ASH 2023 | Immune profiling & MRD negativity of NDMM treated with quadruplet induction+autoSCT: MILESTONE trial
Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, discusses the findings of an analysis from the Phase II MILESTONE study (NCT04991103) in which immune profiling was performed on the bone marrow (BM) and peripheral blood (PB) of patients with newly diagnosed multiple myeloma (NDMM) who underwent quadruplet induction with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), followed by either autologous stem cell transplantation (autoSCT) or consolidation and maintenance, depending on measurable residual disease (MRD) status. Immune subsets were identified in samples at three time points, and Dr Bal outlines the effect of treatment on their composition. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies
Honoraria: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies, MJH Life Sciences
Research Funding: BMS, Adaptive Biotechnologies, Amyloid Foundation, BeiGene, Fate Therapeutics
Educational Content Development: MJH Life Sciences
